Smruthy Sivakumar
YOU?
Author Swipe
View article: Supplementary Tables S1-S24 from Integrative Analysis of a Large Real-World Cohort of Small Cell Lung Cancer Identifies Distinct Genetic Subtypes and Insights into Histologic Transformation
Supplementary Tables S1-S24 from Integrative Analysis of a Large Real-World Cohort of Small Cell Lung Cancer Identifies Distinct Genetic Subtypes and Insights into Histologic Transformation Open
Supplementary Table S1: First-, second-, and third-line systemic therapy in the SCLC clinical cohort. Supplementary Table S2: Genes analyzed as part of this study. Supplementary Table S3: Prevalence of alterations in the genes analyzed. Su…
View article: Supplementary Figures S1-S22 from Integrative Analysis of a Large Real-World Cohort of Small Cell Lung Cancer Identifies Distinct Genetic Subtypes and Insights into Histologic Transformation
Supplementary Figures S1-S22 from Integrative Analysis of a Large Real-World Cohort of Small Cell Lung Cancer Identifies Distinct Genetic Subtypes and Insights into Histologic Transformation Open
Figure S1: Patterns of tumor mutational burden across different ancestry groups. Figure S2: Spectrum of TP53 and RB1 mutations in SCLC. Figure S3: Gene alteration landscape detected from targeted sequencing of liquid biopsies. Figure S4: C…
View article: Supplementary table 1 from Unique Spectrum of Activating <i>BRAF</i> Alterations in Prostate Cancer
Supplementary table 1 from Unique Spectrum of Activating <i>BRAF</i> Alterations in Prostate Cancer Open
Supplementary table 1
View article: Supplementary Figure 4 from Biology and Targetability of the Extended Spectrum of <i>PIK3CA</i> Mutations Detected in Breast Carcinoma
Supplementary Figure 4 from Biology and Targetability of the Extended Spectrum of <i>PIK3CA</i> Mutations Detected in Breast Carcinoma Open
Supplementary Figure 4. Impact of ctDNA fraction on sensitivity of detection of PIK3CAmutations.
View article: Supplementary Data 1 from Unique Spectrum of Activating <i>BRAF</i> Alterations in Prostate Cancer
Supplementary Data 1 from Unique Spectrum of Activating <i>BRAF</i> Alterations in Prostate Cancer Open
Supplementary Data
View article: Supplementary Figure S3 from Genetic Heterogeneity and Tissue-specific Patterns of Tumors with Multiple <i>PIK3CA</i> Mutations
Supplementary Figure S3 from Genetic Heterogeneity and Tissue-specific Patterns of Tumors with Multiple <i>PIK3CA</i> Mutations Open
Patterns of mutual exclusivity as well as co-occurrence between multi-PIK3CA mutations and alterations in other cancer associated genes.
View article: Supplementary Figure 6 from Biology and Targetability of the Extended Spectrum of <i>PIK3CA</i> Mutations Detected in Breast Carcinoma
Supplementary Figure 6 from Biology and Targetability of the Extended Spectrum of <i>PIK3CA</i> Mutations Detected in Breast Carcinoma Open
Supplementary Figure 6. OTHERm variants show a range of subclonality andindependent oncogenicity
View article: Supplementary Figure S4 from Genetic Heterogeneity and Tissue-specific Patterns of Tumors with Multiple <i>PIK3CA</i> Mutations
Supplementary Figure S4 from Genetic Heterogeneity and Tissue-specific Patterns of Tumors with Multiple <i>PIK3CA</i> Mutations Open
Mutual exclusivity of multi-PIK3CA mutations with other gene alterations in the PI3K pathway.
View article: Supplementary Figure S2 from Genetic Heterogeneity and Tissue-specific Patterns of Tumors with Multiple <i>PIK3CA</i> Mutations
Supplementary Figure S2 from Genetic Heterogeneity and Tissue-specific Patterns of Tumors with Multiple <i>PIK3CA</i> Mutations Open
Breakdown of the different tumor types among double-PIK3CA mutant samples based on their clonality and cis/trans status.
View article: Supplementary Figure 5 from Biology and Targetability of the Extended Spectrum of <i>PIK3CA</i> Mutations Detected in Breast Carcinoma
Supplementary Figure 5 from Biology and Targetability of the Extended Spectrum of <i>PIK3CA</i> Mutations Detected in Breast Carcinoma Open
Supplementary Figure 5. Comparison of performance of comprehensive genomicprofiling by next-generation sequencing (NGS) and PCR hotspot testing.
View article: Supplementary Figure 1 from Unique Spectrum of Activating <i>BRAF</i> Alterations in Prostate Cancer
Supplementary Figure 1 from Unique Spectrum of Activating <i>BRAF</i> Alterations in Prostate Cancer Open
Supplementary Figure 1
View article: Supplementary Figure 8 from Biology and Targetability of the Extended Spectrum of <i>PIK3CA</i> Mutations Detected in Breast Carcinoma
Supplementary Figure 8 from Biology and Targetability of the Extended Spectrum of <i>PIK3CA</i> Mutations Detected in Breast Carcinoma Open
Supplementary Figure 8. Overall survival among patients with PIK3CA-mutatedHR+HER2- breast cancer treated with alpelisib/fulvestrant versus fulvestrant alone.
View article: Supplementary Figure 3 from Biology and Targetability of the Extended Spectrum of <i>PIK3CA</i> Mutations Detected in Breast Carcinoma
Supplementary Figure 3 from Biology and Targetability of the Extended Spectrum of <i>PIK3CA</i> Mutations Detected in Breast Carcinoma Open
Supplementary Figure 3. PIK3CA variants detected in paired tissue and liquid samples.
View article: Supplementary Figure S1 from Genetic Heterogeneity and Tissue-specific Patterns of Tumors with Multiple <i>PIK3CA</i> Mutations
Supplementary Figure S1 from Genetic Heterogeneity and Tissue-specific Patterns of Tumors with Multiple <i>PIK3CA</i> Mutations Open
Read support for double-PIK3CA mutation pairs in the determination of cis/trans status.
View article: Supplementary Figure 1 from Biology and Targetability of the Extended Spectrum of <i>PIK3CA</i> Mutations Detected in Breast Carcinoma
Supplementary Figure 1 from Biology and Targetability of the Extended Spectrum of <i>PIK3CA</i> Mutations Detected in Breast Carcinoma Open
Supplementary Figure 1. CONSORT diagram of genomic analyses cohorts
View article: Supplementary Figure 2 from Biology and Targetability of the Extended Spectrum of <i>PIK3CA</i> Mutations Detected in Breast Carcinoma
Supplementary Figure 2 from Biology and Targetability of the Extended Spectrum of <i>PIK3CA</i> Mutations Detected in Breast Carcinoma Open
Supplementary Figure 2. CONSORT diagrams for the cohorts with clinicogenomic data
View article: Supplementary Figure S7 from Genetic Heterogeneity and Tissue-specific Patterns of Tumors with Multiple <i>PIK3CA</i> Mutations
Supplementary Figure S7 from Genetic Heterogeneity and Tissue-specific Patterns of Tumors with Multiple <i>PIK3CA</i> Mutations Open
Serine and threonine phosphoproteome of NIH-3T3 cells bearing PIK3CA E726K/H1047R vs H1047R.
View article: Clinicogenomic landscape and function of<i>PIK3CA</i>,<i>AKT1</i>, and<i>PTEN</i>mutations in breast cancer
Clinicogenomic landscape and function of<i>PIK3CA</i>,<i>AKT1</i>, and<i>PTEN</i>mutations in breast cancer Open
Purpose To comprehensively characterize the clinical and genomic landscapes of PIK3CA, AKT1, and PTEN alterations and examine their functional implications in AKT-driven breast cancer. Experimental Design Comprehensive genomic profiling of…
View article: Ligand-activated EGFR/MAPK signaling but not PI3K, are key resistance mechanisms to EGFR-therapy in colorectal cancer
Ligand-activated EGFR/MAPK signaling but not PI3K, are key resistance mechanisms to EGFR-therapy in colorectal cancer Open
Understanding mechanisms of resistance to active therapies is crucial for developing more effective treatments. Here, we investigate resistance to anti-EGFR and anti-VEGF plus chemotherapy treatment in colorectal cancer (CRC) patients from…
View article: Review — Artificial intelligence in breast surgery for older women with breast cancer: A scoping review of the past ten years
Review — Artificial intelligence in breast surgery for older women with breast cancer: A scoping review of the past ten years Open
Despite older women comprising a significant proportion of breast cancer cases, they remain underrepresented in clinical trials and research. This scoping review examines how artificial intelligence (AI) has been applied in breast surgery …
View article: Single-Hit and Multi-hit PIK3CA Short Variant Genomic Alterations in Clinically Advanced Prostate Cancer: A Genomic Landscape Study
Single-Hit and Multi-hit PIK3CA Short Variant Genomic Alterations in Clinically Advanced Prostate Cancer: A Genomic Landscape Study Open
View article: Supplementary Figure 1 from Unique spectrum of activating <i>BRAF</i> alterations in prostate cancer
Supplementary Figure 1 from Unique spectrum of activating <i>BRAF</i> alterations in prostate cancer Open
Supplementary Figure 1
View article: Supplementary Figure 1 from Unique spectrum of activating <i>BRAF</i> alterations in prostate cancer
Supplementary Figure 1 from Unique spectrum of activating <i>BRAF</i> alterations in prostate cancer Open
Supplementary Figure 1
View article: Supplementary table 1 from Unique spectrum of activating <i>BRAF</i> alterations in prostate cancer
Supplementary table 1 from Unique spectrum of activating <i>BRAF</i> alterations in prostate cancer Open
Supplementary table 1
View article: Supplementary Tables S1-S24 from Integrative analysis of a large real-world cohort of small cell lung cancer identifies distinct genetic subtypes and insights into histological transformation
Supplementary Tables S1-S24 from Integrative analysis of a large real-world cohort of small cell lung cancer identifies distinct genetic subtypes and insights into histological transformation Open
Supplementary Table S1: First-, second-, and third-line systemic therapy in the SCLC clinical cohort. Supplementary Table S2: Genes analyzed as part of this study. Supplementary Table S3: Prevalence of alterations in the genes analyzed. Su…
View article: Data from Integrative analysis of a large real-world cohort of small cell lung cancer identifies distinct genetic subtypes and insights into histological transformation
Data from Integrative analysis of a large real-world cohort of small cell lung cancer identifies distinct genetic subtypes and insights into histological transformation Open
Small cell lung cancer (SCLC) is a recalcitrant neuroendocrine carcinoma with dismal survival outcomes. A major barrier in the field has been the relative paucity of human tumors studied. Here we provide an integrated analysis of 3,600 “re…
View article: Supplementary Data 1 from Unique spectrum of activating <i>BRAF</i> alterations in prostate cancer
Supplementary Data 1 from Unique spectrum of activating <i>BRAF</i> alterations in prostate cancer Open
Supplementary Data
View article: Supplementary Figures S1-S22 from Integrative analysis of a large real-world cohort of small cell lung cancer identifies distinct genetic subtypes and insights into histological transformation
Supplementary Figures S1-S22 from Integrative analysis of a large real-world cohort of small cell lung cancer identifies distinct genetic subtypes and insights into histological transformation Open
Figure S1: Patterns of tumor mutational burden across different ancestry groups. Figure S2: Spectrum of TP53 and RB1 mutations in SCLC. Figure S3: Gene alteration landscape detected from targeted sequencing of liquid biopsies. Figure S4: C…
View article: Data from Unique spectrum of activating <i>BRAF</i> alterations in prostate cancer
Data from Unique spectrum of activating <i>BRAF</i> alterations in prostate cancer Open
Purpose:Alterations in BRAF have been reported in 3-5% of prostate cancer, although further characterization is lacking. Here, we describe the nature of BRAF alterations in prostate cancer using a large cohort from commercially available t…
View article: Supplementary table 2 from Unique spectrum of activating <i>BRAF</i> alterations in prostate cancer
Supplementary table 2 from Unique spectrum of activating <i>BRAF</i> alterations in prostate cancer Open
Supplementary table 2